Pfizer Upgraded To Overweight; Goldman Downgrades Kimco To Sell

Nov. 29, 2016 3:23 PM ETCTSH, PFE, T, ZBH, SAIC, LABL, JNJ, KIM
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Value, Growth At A Reasonable Price

Contributor Since 2013

Finbox is an online stock research platform designed for individual investors and asset managers who care about understanding a stock’s fundamental value. The platform provides a quick sanity check so that investors can understand what they’re investing in and why.

Here are today's top Wall Street analyst ratings where's unbiased fair value estimates support the recommendation.

Top Upgrades
  • Cantor Fitzgerald raised Cognizant Technology Solutions' (CTSH) target price to $67 per share.'s fair value estimate is slightly lower at $66 per share implying 18% upside.

  • Barclays upgraded Pfizer (PFE) from Equal Weight to Overweight. Twelve valuation models suggest the stock is currently 15% undervalued.

  • Jefferies Group reiterated its Buy rating on AT&T (T). Eleven valuation models imply a fair value of $45.50 per share representing 15% upside.

  • Citigroup upgraded Zimmer Biomet (ZBH). The rating change is supported by the company's underlying fundamentals.

Top Downgrades
  • Citigroup downgraded Science Applications International (SAIC). Shares are currently trading at a 24% premium.

  • KeyCorp downgraded Multi-Color Corp (LABL) from Sector Weight to Underweight. Ten free cash flow models imply the stock is 20% overvalued.

  • Barclays downgraded Johnson & Johnson (JNJ) from Overweight to Equal Weight. Fundamentals support the rating change.

  • Goldman Sachs downgraded Kimco Realty (KIM) from Neutral to Sell. Eight valuation models support the rating and conclude a negative 14% margin of safety.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.